COMPULSORY LICENSING


A STEP INTO THE UNKNOWN: INDIA’S FIRST COMPULSORY LICENCE


For the fi rst time in the history of the Indian patent system, a compulsory licence has been granted. Archana Shankar considers the implications.


T e licence was granted to Natco Pharma, a generic drug company, for sorafenib tosylate, a life- extending drug developed, patented and launched by Bayer Corporation. T is drug is sold under the trade name of Nexavar and is used for the treatment of advanced-stage kidney and liver cancer.


T e Controller General of Patents has set a benchmark in this landmark decision by invoking Section 84(1), a crucial provision of the Indian Patents Act which allows any person interested


60 Life Sciences Intellectual Property Review 2012 www.worldipreview.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64